Vulvodynia Clinical Trials 2023

Browse 8 Vulvodynia Medical Studies Across 8 Cities

12 Vulvodynia Clinics

Reviewed by Michael Gill, B. Sc.
8 Vulvodynia Clinical Trials Near Me
Top Hospitals for Vulvodynia Clinical Trials
Image of Sexual Health Research Laboratory, Department of Psychology, Queen's University in Ontario.
Sexual Health Research Laboratory, Department of Psychology, Queen's University
Kingston
1Active Trials
1All Time Trials for Vulvodynia
2023First Vulvodynia Trial
Image of Research Center of the Centre Hospitalier Universitaire de Sherbrooke in Quebec.
Research Center of the Centre Hospitalier Universitaire de Sherbrooke
Sherbrooke
1Active Trials
1All Time Trials for Vulvodynia
2023First Vulvodynia Trial
Image of Centre hospitalier universitaire de Sherbrooke in Quebec.
Centre hospitalier universitaire de Sherbrooke
Sherbrooke
1Active Trials
2All Time Trials for Vulvodynia
2022First Vulvodynia Trial
Image of Exogenia in Quebec.
Exogenia
Sherbrooke
1Active Trials
1All Time Trials for Vulvodynia
2022First Vulvodynia Trial
Image of EvoScient Gynecology in Virginia.
EvoScient Gynecology
Virginia Beach
1Active Trials
1All Time Trials for Vulvodynia
2022First Vulvodynia Trial
Top Cities for Vulvodynia Clinical Trials
Image of Sherbrooke in Quebec.
Sherbrooke
3Active Trials
Research Center of the Centre Hospitalier Universitaire de SherbrookeTop Active Site
Image of Portland in Oregon.
Portland
2Active Trials
Oregon Health and Science UniversityTop Active Site
Vulvodynia Clinical Trials by Phase of TrialVulvodynia Clinical Trials by Age GroupMost Recent Vulvodynia Clinical TrialsTop Treatments for Vulvodynia Clinical Trials
Treatment Name
Active Vulvodynia Clinical Trials
All Time Trials for Vulvodynia
First Recorded Vulvodynia Trial
3 month PelvicSense(R) program
1
1
2023
Experimental: Real Dry needling
1
1
2023
High Intensity Laser Therapy (HILT)
1
1
2022
BioNourish, a component of the Flourish HEC kit
1
1
2022
Traditional Vestibulectomy
1
1
2022

What Are Vulvodynia Clinical Trials?

Vulvodynia is a condition in which women experience unexplained and persistent vulva pain. This is the genital area which includes the surrounding skin of the vaginal opening. So far, the exact cause of Vulvodynia is not identified. Also, the location, severity, and constancy of the pain triggered by Vulvodynia varies from suffers. Vulvodynia can happen to females of all age groups. It can become a serious and long-term problem leading to lower sex drive, which can further impact your relationship. It can cause other complications as well, such as:

  • Anxiety 
  • Depression
  • Sexual dysfunction
  • Lack of sleep

Vulvodynia clinical trials focus on finding the exact cause, the best solutions, and safe treatments to minimize pain and alleviate the condition.

Why Is Vulvodynia Being Studied Through Clinical Trials?

Studies show that nearly 16 percent of women in the US experience Vulvodynia in their lifetime. Moreover, around 7 percent to 8 percent of women experience symptoms of Vulvodynia by the age of forty. Symptoms include persistent pain. The pain is usually a burning and throbbing sensation triggered by sex or when using a tampon. The condition is likely to worsen when sitting. It is often limited to the vulva area but can sometimes spread to the entire genital area.

Therefore, Vulvodynia clinical trials are conducted to determine its impact on women and their personal lives. Through research and trials, analysts can find better therapies and treatments to help ease women from persistent pain and ensure they enjoy quality living.

What Are the Types of Treatments Available for Vulvodynia?

There are many treatments available for Vulvodynia. For example, a randomized clinical trial showed the efficacy of CBT (cognitive behavioral therapy) and SPT (supportive psychotherapy) in women. 

It was a 10-week treatment and a one-year follow-up assessment. CBT resulted in more significant improvement in the severity of pain and sexual function compared to SPT. Cognitive behavioral therapy focuses on teaching patients self-management and pain-relevant coping mechanisms. It yielded greater satisfaction and excellent outcomes in patients.

Other treatments include oral medication like tricyclic antidepressants and antihistamines to reduce itching. The use of Lidocaine ointment also helps relieve pain but temporarily.

What Are Some Recent Breakthrough Clinical Trials for Vulvodynia?

Many clinical trials have been performed over the years to learn more about Vulvodynia and ways to treat it. Some of the breakthrough trials include:

2008: Use of Transcutaneous Electrical Stimulation-The clinical trial was conducted to determine the efficacy and safety of trans nerve stimulation and biofeedback physical therapy for Vulvodynia. 145 Patients got biofeedback and trans electrical nerve therapy weekly with FES (functional electrical stimulation). They completed a total of 10 applications. The results were satisfactory. The patients experienced an improvement in pain by 75.8 percent.

2023: Therapy With Local Anesthetics to Treat Vulvodynia. This research investigated the efficacy of TLA (therapy with local anesthetics) in females suffering from severe Vulvodynia. The results showed a reduction in pain among patients for four to six months.  

Who Are Some of the Key Opinion Leaders/Researchers/Institutions Conducting Vulvodynia Clinical Trial Research?

National Vulvodynia Association

NVA is a leading and top-rated non-profit dedicated to improving women's quality of life and health with Vulvodynia through education and ongoing support. It also invests in research to find effective treatments and cures. 

Musolf Karen L. Musolf

She is the M.D., Assistant Professor, and Vulvodynia Clinic director. She is experienced and well-known for her research on women's health conditions like chronic vaginitis and Vulvodynia.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 22nd, 2021

Last Reviewed: August 27th, 2023

References1 Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006 Jun 1;193(11):1478-86. doi: 10.1086/503780. Epub 2006 Apr 26. https://pubmed.ncbi.nlm.nih.gov/166522742 Bradshaw CS, Morton AN, Hocking J, Garland SM, Morris MB, Moss LM, Horvath LB, Kuzevska I, Fairley CK. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006 Jun 1;193(11):1478-86. Epub 2006 Apr 26. https://pubmed.ncbi.nlm.nih.gov/166522743 Chidawanyika T, Yi CHC, Kelly-Martin R, Cleland J, DuPriest E. Clinical trial to survey results of Flourish vaginal care system for recurrent BV [A80]. Obstet Gynecol. 2022;139:24S. doi:10.1097/01.AOG.0000826648.49549.01 https://doi.org/10.1097/01.AOG.0000826648.49549.014 De Seta F, Campisciano G, Zanotta N, Ricci G, Comar M. The Vaginal Community State Types Microbiome-Immune Network as Key Factor for Bacterial Vaginosis and Aerobic Vaginitis. Front Microbiol. 2019 Oct 30;10:2451. doi: 10.3389/fmicb.2019.02451. eCollection 2019. https://pubmed.ncbi.nlm.nih.gov/317368985 Sobel JD, Schmitt C, Meriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin. J Infect Dis. 1993 Mar;167(3):783-4. doi: 10.1093/infdis/167.3.783. No abstract available. https://pubmed.ncbi.nlm.nih.gov/84409526 Pagan L, Ederveen RAM, Huisman BW, Schoones JW, Zwittink RD, Schuren FHJ, Rissmann R, Piek JMJ, van Poelgeest MIE. The Human Vulvar Microbiome: A Systematic Review. Microorganisms. 2021 Dec 12;9(12). pii: 2568. doi: 10.3390/microorganisms9122568. Review. https://pubmed.ncbi.nlm.nih.gov/349461697 Doerflinger SY, Throop AL, Herbst-Kralovetz MM. Bacteria in the vaginal microbiome alter the innate immune response and barrier properties of the human vaginal epithelia in a species-specific manner. J Infect Dis. 2014 Jun 15;209(12):1989-99. doi: 10.1093/infdis/jiu004. Epub 2014 Jan 7. https://pubmed.ncbi.nlm.nih.gov/244035608 Liao Z, Chakrabarty A, Mu Y, Bhattacherjee A, Goestch M, Leclair CM, Smith PG. A Local Inflammatory Renin-Angiotensin System Drives Sensory Axon Sprouting in Provoked Vestibulodynia. J Pain. 2017 May;18(5):511-525. doi: 10.1016/j.jpain.2016.12.008. Epub 2017 Jan 3. https://pubmed.ncbi.nlm.nih.gov/280623099 Bedford L, Parker SE, Davis E, Salzman E, Hillier SL, Foxman B, Harlow BL. Characteristics of the vaginal microbiome in women with and without clinically confirmed vulvodynia. Am J Obstet Gynecol. 2020 Sep;223(3):406.e1-406.e16. doi: 10.1016/j.ajog.2020.02.039. Epub 2020 Mar 2. https://pubmed.ncbi.nlm.nih.gov/3213514210 Bornstein J, Goldstein AT, Stockdale CK, Bergeron S, Pukall C, Zolnoun D, Coady D; consensus vulvar pain terminology committee of the International Society for the Study of Vulvovaginal Disease (ISSVD), the International Society for the Study of Women's Sexual Health (ISSWSH), and the International Pelvic Pain Society (IPPS). 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. Obstet Gynecol. 2016 Apr;127(4):745-751. doi: 10.1097/AOG.0000000000001359. https://pubmed.ncbi.nlm.nih.gov/27008217